Gilead/Galapagos' Trailing JAK1 Filgotinib Boosted By AS Trial

Gilead and Galapagos have more decent clinical data for filgotinib tucked under their belt as the JAK1 inhibitor shows benefit in another indication, ankylosing spondylitis, with a safety profile that remains reassuring.